1 Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J,
Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U,
Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S,
Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann
M, Martens UM, Thuss-Patience P, Egger M, Block A,
Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F,
Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C,
Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF,
Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle
S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A,
Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M,
Schmalenberg H, Hofheinz RD and FLOT4-AIO Investigators:
Perioperative chemotherapy with fluorouracil plus leucovorin,
oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus
cisplatin and epirubicin for locally advanced, resectable gastric
or gastro-oesophageal junction adenocarcinoma (FLOT4): a
randomised, phase 2/3 trial. Lancet 393(10184): 1948-1957,
2019. PMID: 30982686. DOI: 10.1016/S0140-6736(18)32557-1
2 Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M,
Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H,
Higashino M, Yamamura Y, Kurita A, Arai K and ACTS-GC
Group: Adjuvant chemotherapy for gastric cancer with S-1, an
oral fluoropyrimidine. N Engl J Med 357(18): 1810-1820, 2007.
PMID: 17978289. DOI: 10.1056/NEJMoa072252
3 Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H,
Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and Ohashi Y:
Five-year outcomes of a randomized phase III trial comparing
adjuvant chemotherapy with S-1 versus surgery alone in stage II
or III gastric cancer. J Clin Oncol 29(33): 4387-4393, 2011.
PMID: 22010012. DOI: 10.1200/JCO.2011.36.5908
4 Iwasaki Y, Terashima M, Mizusawa J, Katayama H, Nakamura
K, Katai H, Yoshikawa T, Ito S, Kaji M, Kimura Y, Hirao M,
Yamada M, Kurita A, Takagi M, Lee SW, Takagane A, Yabusaki
H, Hihara J, Boku N, Sano T and Sasako M: Gastrectomy with
383
Urakawa et al: NLR and Pathological Tumor Response
10
11
12
13 Oba T, Maeno K, Takekoshi D, Ono M, Ito T, Kanai T and Ito
KI: Neoadjuvant chemotherapy-induced decrease of prognostic
nutrition index predicts poor prognosis in patients with breast
cancer. BMC Cancer 20(1): 160, 2020. PMID: 32106833. DOI:
10.1186/s12885-020-6647-4
14 Hirahara T, Arigami T, Yanagita S, Matsushita D, Uchikado Y,
Kita Y, Mori S, Sasaki K, Omoto I, Kurahara H, Maemura K,
Okubo K, Uenosono Y, Ishigami S and Natsugoe S: Combined
neutrophil-lymphocyte ratio and platelet-lymphocyte ratio
predicts chemotherapy response and prognosis in patients with
advanced gastric cancer. BMC Cancer 19(1): 672, 2019. PMID:
31286873. DOI: 10.1186/s12885-019-5903-y
15 Miyamoto R, Inagawa S, Sano N, Tadano S, Adachi S and
Yamamoto M: The neutrophil-to-lymphocyte ratio (NLR)
predicts short-term and long-term outcomes in gastric cancer
patients. Eur J Surg Oncol 44(5): 607-612, 2018. PMID:
29478743. DOI: 10.1016/j.ejso.2018.02.003
16 Aoyama T, Hara K, Kazama K and Maezawa Y: Clinical impact
of nutrition and inflammation assessment tools in gastric cancer
treatment. Anticancer Res 42(11): 5167-5180, 2022. PMID:
36288879. DOI: 10.21873/anticanres.16023
17 Giese MA, Hind LE and Huttenlocher A: Neutrophil plasticity
in the tumor microenvironment. Blood 133(20): 2159-2167,
2019. PMID: 30898857. DOI: 10.1182/blood-2018-11-844548
18 Gong W, Zhao L, Dong Z, Dou Y, Liu Y, Ma C and Qu X: After
neoadjuvant chemotherapy platelet/lymphocyte ratios negatively
correlate with prognosis in gastric cancer patients. J Clin Lab Anal
32(5): e22364, 2018. PMID: 29251364. DOI: 10.1002/jcla.22364
19 Jin H, Sun J, Zhu K, Liu X, Zhang Q, Shen Q, Gao Y and Yu J:
The prognostic value of neutrophil-lymphocyte ratio is superior
to derived neutrophil-lymphocyte ratio in advanced gastric
cancer treated with preoperative chemotherapy and sequential
R0 resection: a 5-year follow-up. Onco Targets Ther 10: 26552664, 2017. PMID: 28579803. DOI: 10.2147/OTT.S135641
20 Min KW, Kwon MJ, Kim DH, Son BK, Kim EK, Oh YH and
Wi YC: Persistent elevation of postoperative neutrophil-tolymphocyte ratio: A better predictor of survival in gastric cancer
than elevated preoperative neutrophil-to-lymphocyte ratio. Sci
Rep 7(1): 13967, 2017. PMID: 29070814. DOI: 10.1038/s41598017-13969-x
21 Li Z, Li S, Ying X, Zhang L, Shan F, Jia Y and Ji J: The clinical
value and usage of inflammatory and nutritional markers in
survival prediction for gastric cancer patients with neoadjuvant
chemotherapy and D2 lymphadenectomy. Gastric Cancer 23(3):
540-549, 2020. PMID: 32072387. DOI: 10.1007/s10120-01901027-6
or without neoadjuvant S-1 plus cisplatin for type 4 or large type
3 gastric cancer (JCOG0501): an open-label, phase 3,
randomized controlled trial. Gastric Cancer 24(2): 492-502,
2021. PMID: 33200303. DOI: 10.1007/s10120-020-01136-7
Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, Ryu
MH, Rha SY, Chung IJ, Kim IH, Oh SC, Park YS, Son T, Jung
MR, Heo MH, Kim HK, Park C, Yoo CH, Choi JH, Zang DY,
Jang YJ, Sul JY, Kim JG, Kim BS, Beom SH, Cho SH, Ryu SW,
Kook MC, Ryoo BY, Kim HK, Yoo MW, Lee NS, Lee SH, Kim
G, Lee Y, Lee JH and Noh SH: PRODIGY: A phase III study of
neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and
adjuvant S-1 versus surgery and adjuvant S-1 for resectable
advanced gastric cancer. J Clin Oncol 39(26): 2903-2913, 2021.
PMID: 34133211. DOI: 10.1200/JCO.20.02914
Fukagawa T, Katai H, Mizusawa J, Nakamura K, Sano T,
Terashima M, Ito S, Yoshikawa T, Fukushima N, Kawachi Y,
Kinoshita T, Kimura Y, Yabusaki H, Nishida Y, Iwasaki Y, Lee
SW, Yasuda T, Sasako M and Stomach Cancer Study Group of
the Japan Clinical Oncology Group: A prospective multiinstitutional validity study to evaluate the accuracy of clinical
diagnosis of pathological stage III gastric cancer (JCOG1302A).
Gastric Cancer 21(1): 68-73, 2018. PMID: 28194522. DOI:
10.1007/s10120-017-0701-1
Kurokawa Y, Shibata T, Sasako M, Sano T, Tsuburaya A,
Iwasaki Y and Fukuda H: Validity of response assessment
criteria in neoadjuvant chemotherapy for gastric cancer
(JCOG0507-A). Gastric Cancer 17(3): 514-521, 2014. PMID:
23999869. DOI: 10.1007/s10120-013-0294-2
Rajabnejad A, Vaida F, Valasek M, Razzaque S, Fanta P, Horgan
S, Bouvet M, Lowy AM and Kelly KJ: Predictors and
significance of histologic response to neoadjuvant therapy for
gastric cancer. J Surg Oncol 123(8): 1716-1723, 2021. PMID:
33735448. DOI: 10.1002/jso.26458
Kato T, Oshikiri T, Goto H, Urakawa N, Hasegawa H, Kanaji S,
Yamashita K, Matsuda T, Nakamura T, Suzuki S and Kakeji Y:
Preoperative neutrophil-to-lymphocyte ratio predicts the
prognosis of esophageal squamous cell cancer patients
undergoing minimally invasive esophagectomy after neoadjuvant
chemotherapy. J Surg Oncol 124(7): 1022-1030, 2021. PMID:
34460103. DOI: 10.1002/jso.26611
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W,
Templeton AJ and Früh M: Neutrophil-to-Lymphocyte ratio
(NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic
markers in patients with non-small cell lung cancer (NSCLC)
treated with nivolumab. Lung Cancer 111: 176-181, 2017.
PMID: 28838390. DOI: 10.1016/j.lungcan.2017.07.024
Japanese Research Society for Gastric Cancer: Japanese
classification of gastric carcinoma. Kanehara & Co, 2017.
Tahara T, Shibata T, Okubo M, Yoshida D, Kawamura T,
Horiguchi N, Ishizuka T, Nagasaka M, Nakagawa Y and Ohmiya
N: Histological evaluations of primary lesions are independently
associated with prognosis in patients with gastric cancer who
receive neoadjuvant chemotherapy. Oncol Lett 13(6): 48924896, 2017. PMID: 28599492. DOI: 10.3892/ol.2017.6040
Received November 29, 2022
Revised December 12, 2022
Accepted December 13, 2022
384
...
論文の公開元へ
